Asset profile
CX11
Small molecule
Evidence outlook · lead readout
NCT07011797 · Obesity
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT07011797: The study randomized 250 participants to placebo or one of four CX11 dosing groups and masked both participants and investigators. Its primary endpoint was a clinical measure of body-weight change, but no trial results or statistical comparison have been posted, so the endpoint cannot yet be judged as met or missed.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.